Difference between revisions of "Team:ETH Zurich"
(Style landing page with sections.) |
(Group paragraphs of each step.) |
||
| Line 18: | Line 18: | ||
<section id="start" class="step"> | <section id="start" class="step"> | ||
| − | <p>Cancer kills over 8 million people every year. That's the entire population of Switzerland!</p> | + | <div> |
| − | + | <p>Cancer kills over 8 million people every year. That's the entire population of Switzerland!</p> | |
| − | + | <p>We need more specific therapies because current approaches result in many side-effects.</p> | |
| − | + | <p>That's why we created CATE: Cancer-Targeting E. coli.</p> | |
| + | </div> | ||
<img src="https://static.igem.org/mediawiki/2017/9/99/T--ETH_Zurich--CH.png" class="CH"> | <img src="https://static.igem.org/mediawiki/2017/9/99/T--ETH_Zurich--CH.png" class="CH"> | ||
| + | <a href="https://2017.igem.org/Team:ETH_Zurich/Background" class="more">Learn more</a> | ||
</section> | </section> | ||
| − | <section id="second" class="step"> | + | <section id="second" class="step invert"> |
| + | <div> | ||
| + | <p>CATE consists of the non-pathogenic bacterium E. coli Nissle that has the intrinsic ability to home specifically in tumors.<br><br> We are engineering E. coli Nissle to carry a MRI contrast and a cytotoxic agent so it can deliver both components to tumor sites.</p> | ||
| + | </div> | ||
<img src="https://static.igem.org/mediawiki/2017/0/02/T--ETH_Zurich--Ec.png" class="Ec"> | <img src="https://static.igem.org/mediawiki/2017/0/02/T--ETH_Zurich--Ec.png" class="Ec"> | ||
| − | |||
<a href="https://2017.igem.org/Team:ETH_Zurich/Description" class="more">Project description</a> | <a href="https://2017.igem.org/Team:ETH_Zurich/Description" class="more">Project description</a> | ||
</section> | </section> | ||
<section id="third" class="step"> | <section id="third" class="step"> | ||
| − | <p>CATE is administered intravenously, travels through the blood and colonizes tumors where the bacteria form a highly dense layer between the live and dead zone of the tumor</p> | + | <div> |
| + | <p>CATE is administered intravenously, travels through the blood and colonizes tumors where the bacteria form a highly dense layer between the live and dead zone of the tumor</p> | ||
| + | <p class="alignright">The high density of bacterial cells and the overproduction of lactate by the tumor together activate the first steps of CATE.</p> | ||
| + | </div> | ||
<img src="https://static.igem.org/mediawiki/2017/8/8c/T--ETH_Zurich--ANDgate.png" class="AND"> | <img src="https://static.igem.org/mediawiki/2017/8/8c/T--ETH_Zurich--ANDgate.png" class="AND"> | ||
| − | |||
<a href="https://2017.igem.org/Team:ETH_Zurich/#" class="more">Design</a> | <a href="https://2017.igem.org/Team:ETH_Zurich/#" class="more">Design</a> | ||
</section> | </section> | ||
Revision as of 14:07, 17 October 2017
Cancer kills over 8 million people every year. That's the entire population of Switzerland!
We need more specific therapies because current approaches result in many side-effects.
That's why we created CATE: Cancer-Targeting E. coli.
Learn more
CATE consists of the non-pathogenic bacterium E. coli Nissle that has the intrinsic ability to home specifically in tumors.
We are engineering E. coli Nissle to carry a MRI contrast and a cytotoxic agent so it can deliver both components to tumor sites.
Project description
CATE is administered intravenously, travels through the blood and colonizes tumors where the bacteria form a highly dense layer between the live and dead zone of the tumor
The high density of bacterial cells and the overproduction of lactate by the tumor together activate the first steps of CATE.
Design
